Lv4
550 积分 2021-11-08 加入
EP.12D.03 Characterization of HER2Alterations in 23,321 NSCLC Cases and Real-World Therapeutic Pattern in Chinese HER2-Mutant NSCLC the CHAPTER Study
6个月前
已关闭
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
7个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
7个月前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
7个月前
已完结
NK cells for cancer immunotherapy
7个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
7个月前
已完结
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials
7个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
7个月前
已完结
Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice
7个月前
已完结
皖公网安备34019202002308
